



(12) **DEMANDE DE BREVET CANADIEN**
CANADIAN PATENT APPLICATION
(13) **A1**

(86) Date de dépôt PCT/PCT Filing Date: 2017/12/14 (87) Date publication PCT/PCT Publication Date: 2018/06/21 (85) Entrée phase nationale/National Entry: 2019/05/30 (86) N° demande PCT/PCT Application No.: US 2017/066492 (87) N° publication PCT/PCT Publication No.: 2018/112245 (30) Priorités/Priorities: 2016/12/14 (US62/434,374); 2017/03/30 (US62/478,919); 2017/08/14 (US62/545,380); 2017/11/09 (US62/583,832)	(51) Cl.Int./Int.Cl. <i>A61K 31/00</i> (2006.01), <i>A61K 31/519</i> (2006.01), <i>A61K 9/00</i> (2006.01), <i>A61P 35/00</i> (2006.01) (71) Demandeur/Applicant: PROGENITY INC., US (72) Inventeurs/Inventors: JONES, MITCHELL LAWRENCE, US; SINGH, SHARAT, US; WAHL, CHRISTOPHER LOREN, US; STYLLI, HARRY, US (74) Agent: SMART & BIGGAR
---	--

(54) Titre : TRAITEMENT D'UNE MALADIE DU TRACTUS GASTRO-INTESTINAL AVEC UN INHIBITEUR DE JAK ET DISPOSITIFS ASSOCIES

(54) Title: TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A JAK INHIBITOR AND DEVICES




FIG. 72

(57) **Abrégé/Abstract:**
This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a JAK inhibitor.




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5






FIG. 6






FIG. 9





FIG. 10






FIG. 12




FIG. 13

13/56




FIG. 14

SUBSTITUTE SHEET (RULE 26)




FIG. 15




FIG. 16




FIG. 17




FIG. 18




FIG. 19




FIG. 20




FIG. 21




FIG. 22




FIG. 23




FIG. 24A

FIG. 24B




FIG. 25A




FIG. 25B




FIG. 26A

FIG. 26B




FIG. 27




FIG. 28


4000

FIG. 29




FIG. 30




FIG. 31




FIG. 32




FIG. 33





FIG. 34



^Outlier removed from Group 5

FIG. 35

31/56




FIG. 36






FIG. 37

**FIG. 38****FIG. 39**

33/56




FIG. 40




FIG. 41




FIG. 42




FIG. 43




FIG. 44




FIG. 45




FIG. 46




FIG. 47




FIG. 48




FIG. 49



FIG. 50




FIG. 51

Time	SQ Adalimumab Plasma concentration $\mu\text{g}/\text{ml}$	Topical Adalimumab Plasma concentration $\mu\text{g}/\text{ml}$
6hrs	16 +/-8	0.01
12hrs	13 +/-4	0.01
24hrs	13 +/-3	0.01
48hrs	16 +/-5	0.01

FIG. 52




FIG. 53




Fig. 54




FIG. 55




FIG. 56




FIG. 57




FIG. 58




FIG. 59




FIG. 60




FIG. 61




FIG.62




FIG. 63C




FIG. 63B




FIG. 63A




FIG. 63F




FIG. 63E






FIG. 63D

**FIG. 64****FIG. 65**




FIG. 66




FIG. 67




FIG. 68

Dose response curves Exemptia binding to TNFa (10,000 pg) of Exemptia dispensed from standard injector, Si bellows or PVC bellows.
Error bars = standard deviation. Saline control n-1.

4 hour exposure




FIG. 69

Dose response curves Exemptia binding to TNFa (10,000 pg) of Exemptia dispensed from standard injector, Si bellows or PVC bellows.
Error bars = standard deviation. Saline control n-1.

24 hour exposure




FIG. 70

Dose response curves Exemptia binding to TNFa (10,000 pg) of Exemptia dispensed from standard injector, Si bellows or PVC bellows.

Error bars = standard deviation. Saline control n-1.

336 hour exposure




FIG. 71






FIG. 72

**FIG. 73****FIG. 74**




FIG. 75




FIG. 76




FIG. 72